Supriya Lifescience Limited

As of June 30, 2026, Supriya Lifescience Limited carries a market capitalization of 81.94B, placing it among publicly traded companies globally. Its enterprise value stands at 81.94B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Supriya Lifescience Limited's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Supriya Lifescience Limited has 80.48M shares outstanding.

As of June 30, 2026, Supriya Lifescience Limited trades at a trailing price-to-earnings ratio of 41.29.

As of June 30, 2026, Supriya Lifescience Limited trades at an EV/EBITDA multiple of 28.32 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 9.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.70 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 81.94B versus a market cap of 81.94B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.33M in revenue per employee across its workforce of 1,190.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Supriya Lifescience Limited recorded 697.85M in income tax expense. That works out to an effective tax rate of 26.02, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.68B, leaving 1.98B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Supriya Lifescience Limited's stock has gained approximately 10.89% over the past 52 weeks. The 50-day moving average sits at 870.52, while the 200-day moving average is 782.23.

Over the twelve months ended June 30, 2026, Supriya Lifescience Limited generated 8.73B in revenue and converted that into 1.98B in net income, yielding earnings per share of 24.65. EBITDA reached 2.89B, while operating income came in at 2.59B.

Over the twelve months ended June 30, 2026, Supriya Lifescience Limited posted a gross margin of 68.07, reflecting its pricing power and cost economics. The operating margin of 29.67 and net profit margin of 22.74 provide insight into operational efficiency.